Daina Graybosch

Silverback Therapeutics Inc (NASDAQ: SBTX) recently raised $277.7 million by selling 13.225 million shares in an initial public offering that were priced at $21 each. The Silverback Analyst: SVB Leerink analyst Daina Graybosch initiated coverage of Silverback Therapeutics with an Outperform...

Shares of catalyst-rich pharma Merck & Co., Inc. (NYSE: MRK) are poised for further upside, according to an analyst at SVB Leerink. The Merck Analyst: Daina Graybosch maintained an Outperform rating on Merck and increased the price target from $95 to $100. The Merck Thesis: Merck shares are...

Merck & Co., Inc. (NYSE: MRK) shares came under pressure in Tuesday's session after the pharma company lowered its full-year guidance. The Merck Analysts Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $107 price target. SVB Leerink analyst Daina Graybosch...

Nektar Therapeutics (NASDAQ: NKTR) crashed more than 30% Friday after the company reported a huge second-quarter sales miss. Nektar also said manufacturing problems may have impacted the results of several studies of its NKTR-214 cancer treatment drug, which it has been testing in combination with...